Assessment of Drugs and Carrier PSD in a Commercial Combinational Dry Powder Inhaler Post Multistage Cascade Impaction Analysis by Raman Imaging

Share Button

Presented at: Drug Delivery to the Lung 23
Authors:
O Olkhovyk 1, R Priore 1, C Vernall 2, R Price 2 and J Shur 2
1.Gateway Analytical,  2.University of Bath
Release Date: Wed., December 5, 2012

Authored by scientists at Gateway Analytical and University of Bath, this poster takes a look at how Raman Chemical Imaging (RCI) was used to investigate the active pharmaceutical ingredients (API), particle size distribution (PSD), carrier (Lactose) PSD and access qualitatively, a degree of API-carrier aggregation in a commercial DPI, ADVAIR DISCUS® 500/50 post multistage cascade impaction analysis.

Poster Summary

Multistage cascade impaction is the accepted analytical method for investigating the aerodynamic particle size of Dry Powder Inhalers (DPI). In addition to the cascade impaction, FDA recommends microscopic evaluation of the sample for “release and stability purposes” to check for the presence of large particles, aggregates and foreign contaminants, changes in morphology and crystal growth for both drug substance and carrier particles even though it is very subjective and not robust testing method.

In this study, RCI was used to investigate the active pharmaceutical ingredients (API) particle size distribution (PSD), carrier (Lactose) PSD and access qualitatively degree of API-carrier aggregation in a commercial DPI, ADVAIR DISCUS® 500/50 post multistage cascade impaction analysis.

Download

Dr. Oksana Olkhovyk Ph.D., plays an important role supporting analytical testing services as the Senior Scientist at Gateway Analytical. She has over 15 years experience in Raman spectroscopy, imaging and material characterization. Dr. Olkhovyk has worked to support hundreds of projects as a scientific liaison between Gateway Analytical and their customers, as well as academic and industrial collaborators.